Back to discover
Drug

Carvedilol

Established medicine
ClassAdrenergic receptor beta antagonistResearchActive indication expansion
Also known as (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol, Coreg, Carvédilol, Carvedilol Phosphate+1 more

(+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol, Coreg, Carvédilol, Carvedilol Phosphate, Carvedilolum.

RxNorm20352ChEMBLCHEMBL723ATCC07AG02UNII0K47UL67F2
4
Research papers
23
Active clinical trials
6
Protein targets
3
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Supplemental approval: CARVEDILOL (ANDA078786)

Regulatory2026-08-27FDA

Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (Treat HF)

Clinical trial2026-07-08Results expected Q4 2028 · ClinicalTrials.gov

The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

Exercise-induced Adrenergic Receptor Signaling as an Immune Adjuvant for Allogeneic Cell Therapies

Clinical trial2026-06-05Results expected Q2 2031 · ClinicalTrials.gov

Mechanism of Masked Hypertension - Intervention

Clinical trial2026-06-01Withdrawn · ClinicalTrials.gov

Supplemental approval: CARVEDILOL (ANDA078786)

Regulatory2024-10-09FDA

Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.

Research2023-09-25Circulation

Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial.

Research2017-08-17JCI insight

Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction.

Research2012-06-14Clinical journal of the American Society of Nephrology : CJASN

Approval: CARVEDILOL (ANDA078786)

Regulatory2009-12-22FDA

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Research1996-05-01The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Carvedilol
Aliases & brands
(+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanolCoregCarvédilolCarvedilol PhosphateCarvedilolum
RxNorm CUI
20352
ChEMBL ID
CHEMBL723
ATC codes
C07AG02
UNII
0K47UL67F2
Primary mechanism
Adrenergic receptor beta antagonist
Regulatory jurisdictions
fda

Pharmacology & targets

6 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Beta-3 adrenergic receptor
ADRB3 · P13945
ANTAGONISTAdrenergic receptor beta antagonist
Beta-1 adrenergic receptor
ADRB1 · P08588
ANTAGONISTAdrenergic receptor beta antagonist
Beta-2 adrenergic receptor
ADRB2 · P07550
ANTAGONISTAdrenergic receptor beta antagonist
Alpha-1A adrenergic receptor
ADRA1A · P35348
ANTAGONISTAdrenergic receptor alpha-1 antagonist
Alpha-1D adrenergic receptor
ADRA1D · P25100
ANTAGONISTAdrenergic receptor alpha-1 antagonist
Alpha-1B adrenergic receptor
ADRA1B · P35368
ANTAGONISTAdrenergic receptor alpha-1 antagonist

Regulatory timeline

3 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2009-12-22
Latest approval
2026-08-27
Authorities
FDA
Total events
3
fdaU.S. Food and Drug Administration· 3 events
2026-08-27Supplemental approval
Supplemental approval: CARVEDILOL (ANDA078786)
Evidence ↗
2024-10-09Supplemental approval
Supplemental approval: CARVEDILOL (ANDA078786)
Evidence ↗
2009-12-22Approval
Approval: CARVEDILOL (ANDA078786)
Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Clinical trials

146 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
146
registered trials across all phases
LATEST COMPLETION 2026
23
Active studies
19
Recruiting
106
Late-stage (III+)
66
Completed
57
Discontinued
PHASE DISTRIBUTIONn = 146
Early Phase 15Phase 114Phase 1 / 25Phase 216Phase 2 / 33Phase 317Phase 454Phase N / A32

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction (DANBLOCK)

Active, not recruitingPH IVKey trialBispebjerg Hospitaln=2,7602035

Baveno VII Criteria-guided Initiation of Non-selective Beta Blocker in Patients With Compensated Advanced Chronic Liver Disease to Reduce Hepatic Decompensation: an Open-label Randomised Controlled Trial

RecruitingPH IVChinese University of Hong Kongn=4742031

Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

RecruitingPH IVKey trialUniversity of Rochestern=2,0002031

A Randomized Controlled Trial of Endoscopic Variceal Ligation Versus Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma

RecruitingPH IVTaipei Veterans General Hospital, Taiwann=1202030

Carvedilol Plus Endoscopic Ligation or Not for the Primary Prevention of Esophageal Variceal Bleeding in Carvedilol Non-responders: a Randomized Controlled Trial

RecruitingPH IVTaipei Veterans General Hospital, Taiwann=802030

Recent completions

Trials that read out recently, adding to the completed evidence base.

Slow-release CArvedilol in Patients With REduced Strain and Preserved Ejection Fraction Heart Failure (CARE-preserved HF): A Prospective Randomized, Double-Blinded, Multicenter Study

CompletedPH IVSeoul National University Bundang Hospitaln=632026

Dose Prediction for Antihypertensive Medications in Cirrhotic Patients Using Simcyp Program: Applications in Clinical Practice

CompletedPH IVKafrelsheikh Universityn=402025

Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

CompletedPH IIChildren's Oncology Groupn=1962025

A Pilot Study of Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

CompletedPH IAbramson Cancer Center at Penn Medicinen=682025

KF2022#4-tutkimus:Beetasalpaajan ja tulehduskipulääkkeen Vaikutus CYP-entsyymivälitteiseen lääkeainemetaboliaan

CompletedN/AHelsinki University Central Hospitaln=122025

Acute Hemodynamic Response to Carvedilol in Children With Clinically Significant Portal Hypertension.

CompletedN/AInstitute of Liver and Biliary Sciences, Indian=402024

Research activity

4 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
19962023
Major research themes2
Anthracyclines1Breast Neoplasms1
Journals, researchers & institutions
Top journals
  • Circulation1
  • Clinical journal of the American Society of Nephrology : CJASN1
  • JCI insight1
  • The New England journal of medicine1
Leading researchers
  • Asosingh K1
  • Borley A1
  • Bristow MR1
  • Broom A1
  • Cheong HI1
  • Cohn JN1
  • Collins G1
  • Colucci WS1
Leading institutions
free-text, unnormalised
  • Beatson Oncology Centre1
  • BHF Centre for Cardiovascular Science (P.A.H.1
  • Columbia University College of Physicians and Surgeons1
  • Edinburgh Centre1
  • Edinburgh Clinical Trials Unit1
  • Golden Jubilee National Hospital1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Candesartan

Studied across 2 of the same disease areas as Carvedilol in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.